About
Cognoa is an early childhood development and pediatric behavioral health company dedicated to enabling earlier, faster, and more equitable diagnosis of autism and other developmental conditions. Their flagship product, Canvas Dx, is the first and only FDA-authorized digital diagnostic solution designed specifically for children aged 18 months to 6 years. Traditional autism diagnosis often takes years, leaving children without critical early interventions. Canvas Dx dramatically shortens this timeline to days, not months, by leveraging artificial intelligence and machine learning to deliver objective, data-driven assessments directly through clinicians. The platform supports remote, digital evaluation, breaking down geographic and systemic barriers to accessing oversubscribed specialty centers. It helps address pervasive diagnostic inequities—girls are diagnosed 1.5 years later than boys on average, and underserved minority children are frequently missed altogether. By reducing reliance on subjective assessment, Canvas Dx provides a standardized, bias-reduced path to diagnosis. Canvas Dx is now reimbursed by Highmark Insurance and has achieved Medicaid coverage in select states, making it increasingly accessible across socioeconomic lines. The solution is designed for healthcare professionals, offering tools for clinical research, performance metrics, and streamlined prescriber workflows. Cognoa's whole-child, responsible AI approach is transforming the diagnostic landscape for pediatric behavioral health, giving families the knowledge and access they need to pursue timely, life-changing care.
Key Features
- FDA-Authorized AI Diagnosis: Canvas Dx is the first and only FDA-authorized digital diagnostic aid for autism in children aged 18 months to 6 years, lending clinical credibility to AI-driven assessments.
- Rapid Turnaround: Delivers diagnosis or ruling-out of autism within days rather than the typical multi-year wait, enabling families to pursue early interventions promptly.
- Remote Digital Evaluation: Enables clinicians to evaluate children remotely, removing geographic barriers and reducing dependence on scarce, oversubscribed specialty centers.
- Bias-Reducing Objective Assessment: Uses objective, data-driven AI methodology to reduce prevalent biases in traditional autism diagnoses, helping underserved and minority children receive equitable care.
- Insurance & Medicaid Coverage: Reimbursed by Highmark Insurance and covered by Medicaid in select states, broadening access for families across diverse socioeconomic backgrounds.
Use Cases
- Pediatricians conducting initial autism screenings can use Canvas Dx to provide a rapid, objective diagnosis or rule-out result without lengthy specialist referrals.
- Healthcare systems in rural or underserved areas can deploy Canvas Dx remotely to give families access to autism diagnostics without traveling to distant specialty centers.
- Developmental researchers can leverage Canvas Dx data and performance metrics for clinical research into early autism detection and intervention outcomes.
- Insurance providers and Medicaid programs can integrate Canvas Dx into reimbursement frameworks to reduce the long-term cost burden of late autism diagnosis.
- Families with developmental concerns about children aged 18 months to 6 years can seek a Canvas Dx prescriber to obtain a fast, clinically validated diagnostic evaluation.
Pros
- First-Mover FDA Authorization: Being the only FDA-authorized AI diagnostic for autism in young children gives Canvas Dx unmatched clinical legitimacy and regulatory trust.
- Dramatically Faster Diagnosis: Reduces diagnostic timelines from years to days, ensuring children access early interventions during the most critical developmental window.
- Addresses Systemic Inequities: Objective AI evaluation actively counters racial, gender, and geographic disparities that frequently delay or prevent autism diagnosis in underserved populations.
- Growing Insurance Coverage: Active reimbursement partnerships with major insurers and Medicaid programs reduce financial barriers for broad adoption.
Cons
- Requires Clinician Prescription: Canvas Dx is only accessible through licensed healthcare professionals, limiting direct family access and requiring an existing clinical relationship.
- Limited Geographic Medicaid Coverage: Medicaid reimbursement is currently available only in select states, restricting cost-free access for low-income families in other regions.
- Narrowly Focused Age Range: Canvas Dx is designed specifically for children aged 18 months to 6 years, and does not address developmental screening needs for older children or adolescents.
Frequently Asked Questions
What is Canvas Dx?
Canvas Dx is an FDA-authorized AI-powered digital diagnostic solution developed by Cognoa that enables clinicians to diagnose or rule out autism spectrum disorder in children aged 18 months to 6 years, typically within days.
Who can use Canvas Dx?
Canvas Dx is available to licensed healthcare professionals, including pediatricians and developmental specialists. Families can access it by finding a Canvas Dx prescriber through Cognoa's website.
How does Cognoa's AI work for autism diagnosis?
Cognoa uses artificial intelligence and machine learning to analyze data collected through a remote, digital evaluation process. This objective, data-driven approach helps identify developmental patterns associated with autism while reducing human bias.
Is Canvas Dx covered by insurance?
Yes. Canvas Dx is currently reimbursed by Highmark Insurance and has achieved Medicaid coverage in select U.S. states. Cognoa continues to expand coverage partnerships.
Why does early autism diagnosis matter?
Early interventions—ideally before age 4—have the greatest positive impact on developmental outcomes. Most children are currently diagnosed after age 4, creating a costly and harmful delay. Canvas Dx shortens this gap significantly.
